The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

 
Trial Details
Trial status:
Closed
Recruitment start date:
01/08/2009
Funder:
The Sue Harris Bone Marrow Trust
Sponsor:
UCL
Chief Investigator:
Dr Rachael Hough
Recruitment target:
60
EudraCT number:
2004-003845-41
Contact details:
ctc-cordblood@ucl.ac.uk
Lay summary:
RIC UCBT
Transplantation of Umbilical Cord Blood from Unrelated Donors in Patients with Haematological Diseases using a Reduced Intensity Conditioning Regimen
Description
Design: RIC-UCBT is a multicentre phase II single-arm trial of reduced-intensity conditioned umbilical cord blood transplantation in patients with haematological diseases.
Treatment: All patients registered received a fludarabine, cyclophosphamide & low-dose total body irradiation conditioned cord blood transplant, followed by standard immunosuppression. They were followed up regularly for at least 2 years post-transplant. 
Key inclusion/exclusion criteria: Patients aged 2-70 years with advanced or high risk haematological diseases (e.g. leukaemia, lymphoma, myeloma, myelodysplastic syndrome) needing transplant, who do not have a matched sibling or unrelated donor available. They must not have had a stem cell transplant within the previous 6 months, and have to be fit for transplant, with adequate liver, kidney, heart and lung function. Patients must not have progressive or refractory disease. Patients with serious active infection or who test positive for HIV or HTLV are not eligible.
Duration of recruitment: 40 months 
Aim
The overall aim of the RIC UCBT trial is to investigate whether reduced intensity cord blood transplantation is safe and effective in controlling haematological diseases.  The study investigates rates of transplant-related mortality, graft-versus-host disease, engraftment, as well as disease progression and survival.
Trial protocols
Trial protocols must not be applied to patients treated outside trials. UCL CTC can only ensure that approved trial investigators are provided with amendments to protocols.
No protocols have been currently made available for download
Trial documents
No documents have been currently made available for download
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us